Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

doi:10.3748/wjg.v16.i10.1177

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6110)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

458

HTML

5184

Figures (1-1)

314

Tables (1-2)

154

Sum=6110

Mar 14, 2010 (publication date) through May 23, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Mar 14, 2010; 16(10): 1177-1187
Published online Mar 14, 2010. doi: 10.3748/wjg.v16.i10.1177

Open in New Tab Full Size Figure Download Figure

Figure 1 Simplified illustration of the epidermal growth factor receptor (EGFR) pathway with the RAS/MAPK and PIK3CA/PTEN cascades. Specific components of the pathway are correlated with resistance to anti-EGFR monoclonal antibodies (moAbs). As shown, KRAS and BRAF mutations are correlated with resistance to anti-EGFR moAbs, while further evaluation is required for PIK3CA mutations and PTEN loss of expression.

Citation: Saridaki Z, Georgoulias V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 2010; 16(10): 1177-1187
URL: https://www.wjgnet.com/1007-9327/full/v16/i10/1177.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i10.1177